Erratum: Spontanous bacterial peritonitis: Recent guidelines and beyond (Gut (2012) 61 (297-310) DOI: 10.1136/gutjnl-2011-300779);Spontaneous bacterial peritonitis: Recent guidelines and beyond

Gut

Volumn 61, Issue 2, 2012, Pages 297-310

  Wiest, Reiner ^a   Krag, A ^b   Gerbes, A ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b HVIDOVRE HOSPITAL   (Denmark)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMOXICILLIN PLUS CLAVULANIC ACID; BACTERIAL DNA; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; LACTATE DEHYDROGENASE; LACTIC ACID; NORFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADJUVANT THERAPY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ASCITES FLUID; AUTOANALYZER; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CELL COUNT; COMMUNICABLE DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FECES MICROFLORA; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; INFECTION COMPLICATION; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; INFLAMMATION; INTESTINE MUCOSA PERMEABILITY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MICROSCOPY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERITONEAL FLUID; PERITONITIS; POLYMORPHONUCLEAR CELL; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPONTANEOUS BACTERIAL PERITONITIS; SURVIVAL TIME;

EID: 84855163970     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300779corr1     Document Type: Erratum

References (166)

1. Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-24. (Pubitemid 47374144)
2. Grange JD, Roulot D, Pelletier G, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial [see comments]. J Hepatol 1998;29:430-6. (Pubitemid 28396660)
3. Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008;48:774-9.
4. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49:2087-107.
5. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-8. (Pubitemid 34032554)
6. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993;18:353-8. (Pubitemid 23279724)
7. Pinzello G, Simonetti RG, Craxi A, et al. Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology 1983;3:545-9. (Pubitemid 13078753)
8. Evans LT, Kim WR, Poterucha JJ, et al. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003;37:897-901. (Pubitemid 36397402)
9. Castellote J, Girbau A, Maisterra S, et al. Spontaneous bacterial peritonitis and bacterascites prevalence in asymptomatic cirrhotic outpatients undergoing large-volume paracentesis. J Gastroenterol Hepatol 2008;23:256-9. (Pubitemid 351257669)
10. Jeffries MA, Stern MA, Gunaratnam NT, et al. Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites undergoing therapeutic paracentesis. Am J Gastroenterol 1999;94:2972-6. (Pubitemid 29482767)
11. Conn HO, Fessel JM. Spontaneous bacterial peritonitis in cirrhosis: variations on a theme. Medicine (Baltimore) 1971;50:161-97.
12. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142-53. (Pubitemid 30039459)
13. Chu CM, Chang KY, Liaw YF. Prevalence and prognostic significance of bacterascites in cirrhosis with ascites. Dig Dis Sci 1995;40:561-5.
14. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-501. (Pubitemid 24359062)
15. Nobre SR, Cabral JE, Gomes JJ, et al. In-hospital mortality in spontaneous bacterial peritonitis: a new predictive model. Eur J Gastroenterol Hepatol 2008;20:1176-81.
16. Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial peritonitisein-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol 2001;96:1232-6. (Pubitemid 32319166)
17. Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988;8:27-31. (Pubitemid 18092054)
18. Toledo C, Salmeron JM, Rimola A, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993;17:251-7. (Pubitemid 23046697)
19. Andreu M, Sola R, Sitges-Serra A, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterol 1993;104:1133-8. (Pubitemid 23090768)
20. Silvain C, Besson I, Ingrand P, et al. Prognosis and long-term recurrence of spontaneous bacterial peritonitis in cirrhosis. J Hepatol 1993;19:188-9. (Pubitemid 23338031)
21. Terg R, Levi D, Lopez P, et al. Analysis of clinical course and prognosis of culture-positive spontaneous bacterial peritonitis and neutrocytic ascites. Evidence of the same disease. Dig Dis Sci 1992;37:1499-504.
22. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010;139:1246-56, 1256.e1-5.
23. Altman C, Grange JD, Amiot X, et al. Survival after a first episode of spontaneous bacterial peritonitis. Prognosis of potential candidates for orthotopic liver transplantation. J Gastroenterol Hepatol 1995;10:47-50.
24. Cheong HS, Kang CI, Lee JA, et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009;48:1230-6.
25. Almdal TP, Skinhoj P. Spontaneous bacterial peritonitis in cirrhosis. Incidence, diagnosis, and prognosis. Scand J Gastroenterol 1987;22:295-300. (Pubitemid 17054300)
26. Terg R, Gadano A, Cartier M, et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int 2009;29:415-19.
27. Franca AV, De Souza JB, Silva CM, et al. Long-term prognosis of cirrhosis after spontaneous bacterial peritonitis treated with ceftriaxone. J Clin Gastroenterol 2001;33:295-8. (Pubitemid 32880967)
28. Kamani L, Mumtaz K, Ahmed US, et al. Outcomes in culture positive and culture negative ascitic fluid infection in patients with viral cirrhosis: cohort study. BMC Gastroenterol 2008;8:59.
29. Umgelter A, Reindl W, Miedaner M, et al. Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 2009;37:2-8.
30. Cho JH, Park KH, Kim SH, et al. Bacteremia is a prognostic factor for poor outcome in spontaneous bacterial peritonitis. Scand J Infect Dis 2007;39:697-702. (Pubitemid 47180470)
31. Appenrodt B, Grunhage F, Gentemann MG, et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010;51:1327-33.
32. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422-33. (Pubitemid 40289486)
33. Wiest R. Role of bacterial infections for hepatorenal syndrome. In: Gerbes A, ed. Frontiers in Gastrointestinal Research. Aszites, Hyponatremia and heptorenal syndrome. Basel, Switzerland: Krager, 2010.
34. Wells CL. Relationship between intestinal microecology and the translocation of intestinal bacteria. Antonie Van Leeuwenhoek 1990;58:87-93. (Pubitemid 20268945)
35. Guarner C, Gonzalez-Navajas JM, Sanchez E, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 2006;44:633-9. (Pubitemid 44433719)
36. Llovet JM, Bartoli R, March F, et al. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J Hepatol 1998;28:307-13. (Pubitemid 28116439)
37. Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011;54:562-72.
38. Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011;53:96-105.
39. Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001;96:2962-7. (Pubitemid 32959540)
40. Guarner C, Runyon BA, Young S, et al. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997;26:1372-8. (Pubitemid 27346652)
41. Pardo A, Bartoli R, Lorenzo-Zuniga V, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 2000;31:858-63. (Pubitemid 30169931)
42. Teltschik Z, Wiest R, Beisner J, et al. Intestinal bacterial translocation in cirrhotic rats is related to compromised Paneth cell antimicrobial host defence. Hepatology (in press).
43. Chiva M, Guarner C, Peralta C, et al. Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats. Eur J Gastroenterol Hepatol 2003;15:145-50. (Pubitemid 36269778)
44. Ramachandran A, Prabhu R, Thomas S, et al. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology 2002;35:622-9. (Pubitemid 34183967)
45. Dunn DL, Barke RA, Ahrenholz DH, et al. The adjuvant effect of peritoneal fluid in experimental peritonitis. Mechanism and clinical implications. Ann Surg 1984;199:37-43. (Pubitemid 14218872)
46. Gabele E, Muhlbauer M, Paulo H, et al. Analysis of monocyte chemotactic protein-1 gene polymorphism in patients with spontaneous bacterial peritonitis. World J Gastroenterol 2009;15:5558-62.
47. Joyce LD, Hau T, Hoffman R, et al. Evaluation of the mechanism of zymosan-induced resistance to experimental peritonitis. Surgery 1978;83:717-25. (Pubitemid 8353307)
48. Runyon BA, Morrissey RL, Hoefs JC, et al. Opsonic activity of human ascitic fluid: a potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology 1985;5:634-7. (Pubitemid 15029736)
49. Such J, Guarner C, Enriquez J, et al. Low C3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J Hepatol 1988;6:80-4. (Pubitemid 18053332)
50. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterol 1986;91:1343-6. (Pubitemid 17176845)
51. Llach J, Rimola A, Navasa M, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992;16:724-7.
52. Novella M, Sola R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997;25:532-6. (Pubitemid 27106428)
53. Wiest R, Leidl F, Kopp A, et al. Peritoneal fluid adipokines: ready for prime time? Eur J Clin Invest 2009;39:219-29.
54. Guarner C, Sola R, Soriano G, et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999;117:414-19. (Pubitemid 29352951)
55. Obstein KL, Campbell MS, Reddy KR, et al. Association between model for end-stage liver disease and spontaneous bacterial peritonitis. Am J Gastroenterol 2007;102:2732-6. (Pubitemid 350179324)
56. Riordan SM, Skinner N, Nagree A, et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 2003;37:1154-64. (Pubitemid 36538693)
57. Wasmuth HE, Kunz D, Yagmur E, et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol 2005;42:195-201. (Pubitemid 40143465)
58. Berres ML, Schnyder B, Yagmur E, et al. Longitudinal monocyte human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis. Liver Int 2009;29:536-43.
59. Hassner A, Kletter Y, Jedvab M, et al. Impaired monocyte function in liver cirrhosis. Lancet 1979;1:329-30. (Pubitemid 9104639)
60. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986;6:252-62. (Pubitemid 16144876)
61. Bruns T, Peter J, Reuken PA, et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int 2011:10-3231.
62. Nischalke HD, Berger C, Aldenhoff K, et al. Toll-like receptor (TLR) 2 promotor and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol 2011;55:1010-16.
63. Netea MG, Ferwerda G, de Jong DJ, et al. Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol 2005;174:6518-23. (Pubitemid 40663847)
64. Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009;104:1130-4.
65. Trikudanathan G, Israel J, Cappa J, et al. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patientsda systematic review and meta-analysis. Int J Clin Pract 2011;65:674-8.
66. Senzolo M, Cholongitas E, Burra P, et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009;29:1189-93.
67. Krag A, Wiest R, Albillos A, et al. Reduced mortality with nonselective betablockers (NSBB) compared to banding is not related to prevention of bleeding or bleeding related mortality: a hypothesis for non-hemodynamic effects of NSBB. J Hepatol 2011;54:S72.
68. Sanders VM, Straub RH. Norepinephrine, the beta-adrenergic receptor, and immunity. Brain Behav Immun 2002;16:290-332.
69. Worlicek M, Knebel K, Linde HJ, et al. Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis. Gut 2010;59:1127-34.
70. Chinnock B, Afarian H, Minnigan H, et al. Physician clinical impression does not rule out spontaneous bacterial peritonitis in patients undergoing emergency department paracentesis. Ann Emerg Med 2008;52:268-73.
71. Hoefs JC. Increase in ascites white blood cell and protein concentrations during diuresis in patients with chronic liver disease. Hepatology 1981;1:249-54. (Pubitemid 11003580)
72. Albillos A, Cuervas-Mons V, Millan I, et al. Ascitic fluid polymorphonuclear cell count and serum to ascites albumin gradient in the diagnosis of bacterial peritonitis. Gastroenterology 1990;98:134-40. (Pubitemid 20017794)
73. Garcia-Tsao G, Conn HO, Lerner E. The diagnosis of bacterial peritonitis: comparison of pH, lactate concentration and leukocyte count. Hepatology 1985;5:91-6. (Pubitemid 15167049)
74. Stassen WN, McCullough AJ, Bacon BR, et al. Immediate diagnostic criteria for bacterial infection of ascitic fluid. Evaluation of ascitic fluid polymorphonuclear leukocyte count, pH, and lactate concentration, alone and in combination. Gastroenterology 1986;90:1247-54. (Pubitemid 16145491)
75. Yang CY, Liaw YF, Chu CM, et al. White count, pH and lactate in ascites in the diagnosis of spontaneous bacterial peritonitis. Hepatology 1985;5:85-90.
76. Campillo B, Richardet JP, Kheo T, et al. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis 2002;35:1-10. (Pubitemid 34666853)
77. Gonzalez-Navajas JM, Bellot P, Frances R, et al. Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. J Hepatol 2008;48:61-7. (Pubitemid 350191990)
78. Angeloni S, Nicolini G, Merli M, et al. Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. Am J Gastroenterol 2003;98:1844-8. (Pubitemid 36959168)
79. Riggio O, Angeloni S, Parente A, et al. Accuracy of the automated cell counters for management of spontaneous bacterial peritonitis. World J Gastroenterol 2008;14:5689-94.
80. Cereto F, Genesca J, Segura R. Validation of automated blood cell counters for the diagnosis of spontaneous bacterial peritonitis. Am J Gastroenterol 2004;99:1400. (Pubitemid 39062283)
81. Nousbaum JB, Cadranel JF, Nahon P, et al. Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology 2007;45:1275-81. (Pubitemid 46775791)
82. Hiscoke C, Yoxall H, Greig D, et al. Validation of a method for the rapid diagnosis of urinary tract infection suitable for use in general practice. Br J Gen Pract 1990;40:403-5.
83. Mendler MH, Agarwal A, Trimzi M, et al. A new highly sensitive point of care screen for spontaneous bacterial peritonitis using the leukocyte esterase method. J Hepatol 2010;53:477-83.
84. Bruns T, Sachse S, Straube E, et al. Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. Liver Int 2009;29:1206-14.
85. Frances R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004;39:484-91. (Pubitemid 38222190)
86. Frances R, Zapater P, Gonzalez-Navajas JM, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008;47:978-85. (Pubitemid 351449689)
87. Zapater P, Frances R, Gonzalez-Navajas JM, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2008;48:1924-31.
88. Chinnock B, Fox C, Hendey GW. Gram's stain of peritoneal fluid is rarely helpful in the evaluation of the ascites patient. Ann Emerg Med 2009;54:78-82.
89. Conn HO. Unusual presentations of SBP. In: Conn HO, Rodes J, Navasa M, eds. London: Informa Healthcare, 2000:47-74.
90. Ortiz J, Soriano G, Coll P, et al. Early microbiologic diagnosis of spontaneous bacterial peritonitis with BacT/ALERT. J Hepatol 1997;26:839-44. (Pubitemid 27145707)
91. Siersema PD, de Marie S, van Zeijl JH, et al. Blood culture bottles are superior to lysis-centrifugation tubes for bacteriological diagnosis of spontaneous bacterial peritonitis. J Clin Microbiol 1992;30:667-9.
92. Castellote J, Xiol X, Verdaguer R, et al. Comparison of two ascitic fluid culture methods in cirrhotic patients with spontaneous bacterial peritonitis. Am J Gastroenterol 1990;85:1605-8.
93. Klaerner HG, Eschenbach U, Kamereck K, et al. Failure of an automated blood culture system to detect nonfermentative gramnegative bacteria. J Clin Microbiol 2000;38:1036-41. (Pubitemid 30140555)
94. Pelletier G, Salmon D, Ink O, et al. Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis. J Hepatol 1990;10:327-31. (Pubitemid 20162740)
95. Gerbes AL, Jungst D, Xie YN, et al. Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence. Cancer 1991;68:1808-14.
96. Wang SS, Lu CW, Chao Y, et al. Malignancy-related ascites: a diagnostic pitfall of spontaneous bacterial peritonitis by ascitic fluid polymorphonuclear cell count. J Hepatol 1994;20:79-84. (Pubitemid 24043089)
97. Casafont F, Rivero M, Fernandez MD, et al. Granulocyte elastase in cirrhotic patients with spontaneous bacterial peritonitis. Dig Dis Sci 1999;44:1985-9. (Pubitemid 29510805)
98. Parsi MA, Saadeh SN, Zein NN, et al. Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology 2008;135:803-7.
99. Soriano G, Castellote J, Alvarez CE, et al. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol 2009;52:39-44.
100. Runyon BA, Hoefs JC. Ascitic fluid analysis in the differentiation of spontaneous bacterial peritonitis from gastrointestinal tract perforation into ascitic fluid. Hepatology 1984;4:447-50. (Pubitemid 14116646)
101. Wu SS, Lin OS, Chen YY, et al. Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation. J Hepatol 2001;34:215-21. (Pubitemid 32176442)
102. Wiest R, Schoelmerich J. Secondary peritonitis in cirrhosis: "Oil in fire". J Hepatol 2009;52:7-9.
103. Song KH, Jeon JH, Park WB, et al. Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum betalactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study. BMC Infect Dis 2009;9:41.
104. Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010;8:979-85.
105. Kresken M, Hafner D, Schmitz FJ, et al. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. 2010. http://www.p-e-g.org
106. Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis [see comments]. Gastroenterology 1996;111:1011-17. (Pubitemid 26327604)
107. Angeloni S, Leboffe C, Parente A, et al. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World J Gastroenterol 2008;14:2757-62.
108. Castellote J, Ariza X, Girbau A, et al. Antibiotic-resistant bacteria in spontanous bacterial peritonitis. Is it time to change? J Hepatol 2010;52:S69.
109. Singh N, Wagener MM, Gayowski T. Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit. Clin Microbiol Infect 2003;9:531-7. (Pubitemid 36833798)
110. Park YH, Lee HC, Song HG, et al. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J Gastroenterol Hepatol 2003;18:927-33. (Pubitemid 37056172)
111. Heo J, Seo YS, Yim HJ, et al. Clinical features and prognosis of spontaneous bacterial peritonitis in korean patients with liver cirrhosis: a multicenter retrospective study. Gut Liver 2009;3:197-204.
112. Campillo B, Dupeyron C, Richardet JP. Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect 2001;127:443-50. (Pubitemid 34092790)
113. Piroth L, Pechinot A, Minello A, et al. Bacterial epidemiology and antimicrobial resistance in ascitic fluid: a 2-year retrospective study. Scand J Infect Dis 2009;41:847-51.
114. Kock R, Becker K, Cookson B, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010;15:19688.
115. Hawser SP, Bouchillon SK, Hoban DJ, et al. Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010;54:3043-6.
116. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008;13:19044.
117. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-66. (Pubitemid 351249250)
118. Tangden T, Cars O, Melhus A, et al. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010;54:3564-8.
119. Walsh TR, Weeks J, Livermore DM, et al. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011;11:355-62.
120. World Health Organisation. Combat Drug Resistance: No Action Today Means No Cure Tomorrow. World Health Day 2011, 2011. http://www.who.int/mediacentre/ multimedia/podcasts/en/
121. Rodriguez-Bano J, Picon E, Gijon P, et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli. J Clin Microbiol 2010;48:1726-31.
122. Rodriguez-Bano J, Picon E, Gijon P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010;50:40-8.
123. Hoban DJ, Bouchillon SK, Hawser SP, et al. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010;54:3031-4.
124. Capp R, Chang Y, Brown DF. Effective Antibiotic Treatment Prescribed by Emergency Physicians in Patients Admitted to the Intensive Care Unit with Severe Sepsis or Septic Shock: Where is the Gap? J Emerg Med. Published Online First: 1 March 2011. PMID: 21371846.
125. Deviere J, Content J, Denys C, et al. Excessive in vitro bacterial lipopolysaccharide-induced production on monokines in cirrhosis. Hepatology 1990;11:628-34. (Pubitemid 20151741)
126. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999;104:1223-33. (Pubitemid 29536293)
127. Runyon BA. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. Hepatology 1990;12:710-15. (Pubitemid 20349255)
128. Runyon BA, McHutchison JG, Antillon MR, et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991;100:1737-42.
129. Runyon BA, Hoefs JC. Spontaneous vs secondary bacterial peritonitis. Differentiation by response of ascitic fluid neutrophil count to antimicrobial therapy. Arch Intern Med 1986;146:1563-5. (Pubitemid 16072327)
130. Fong TL, Akriviadis EA, Runyon BA, et al. Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology 1989;9:423-6. (Pubitemid 19074975)
131. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo- controlled trial. Hepatology 1990;12:716-24. (Pubitemid 20349256)
132. Terg R, Llano K, Cobas SM, et al. Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages. J Hepatol 1998;29:437-42. (Pubitemid 28396661)
133. Singh N, Gayowski T, Yu VL, et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995;122:595-8.
134. Nunnari G, Celesia BM, Bellissimo F, et al. Trimethoprim- sulfamethoxazole-associated severe hypoglycaemia: a sulfonylurea-like effect. Eur Rev Med Pharmacol Sci 2010;14:1015-18.
135. Wagenlehner FM, Schmiemann G, Hoyme U, et al. [National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients] (In German). Urologe A 2011;50:153-69.
136. Fernandez J, Ruiz d A, Gomez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006;131:1049-56.
137. Saab S, Hernandez JC, Chi AC, et al. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009;104:993-1001.
138. Loomba R, Wesley R, Bain A, et al. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol 2009;7:487-93.
139. Runyon BA. A pill a day can improve survival in patients with advanced cirrhosis. Gastroenterology 2007;133:1029-31. (Pubitemid 47374151)
140. Soriano G, Guarner C, Teixido M, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-81.
141. Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008;48:774-9.
142. Koo HL, Dupont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010;26:17-25.
143. Alvarez RF, Mattos AA, Correa EB, et al. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. Arq Gastroenterol 2005;42:256-62. (Pubitemid 43231959)
144. Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995;22:1171-4.
145. Krag A, Wiest R, Gluud LL. Fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis. Am J Gastroenterol 2010;105:1444-5.
146. Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-24. (Pubitemid 47374144)
147. Grange JD, Roulot D, Pelletier G, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial [see comments]. J Hepatol 1998;29:430-6. (Pubitemid 28396660)
148. Dupont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers'diarrhea. Ann Intern Med 2005;142:805-12. (Pubitemid 40664039)
149. Dupont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004;10:1009-11.
150. Darkoh C, Lichtenberger LM, Ajami N, et al. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother 2010;54:3618-24.
151. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol 2005;42(Suppl 1):S85-92. (Pubitemid 40364607)
152. Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol 2006;45:744-57. (Pubitemid 44466668)
153. Chelarescu O, Chelarescu D, Ticovenau E, et al. Propranolol administration on post surgical infections in cirrhotic patients. J.Hepatol 2003;38:A173, (Abstract).
154. Perez-Paramo M, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000;31:43-8. (Pubitemid 30033687)
155. Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017-22.
156. Angeli P. beta-Blockers and refractory ascites in cirrhosis: the message of a team of true scientists. J Hepatol 2011;55:743-4.
157. Serste T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011;55:794-9.
158. Zhang SC, Wang W, Ren WY, et al. Effect of cisapride on intestinal bacterial and endotoxin translocation in cirrhosis. World J Gastroenterol 2003;9:534-8. (Pubitemid 36372122)
159. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-65.
160. Lorenzo-Zuniga V, Bartoli R, Planas R, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003;37:551-7. (Pubitemid 36258776)
161. Lorenzo-Zuniga V, Rodriguez-Ortigosa CM, Bartoli R, et al. Insulin-like growth factor-I improves intestinal barrier function in cirrhotic rats. Gut 2006;55:1306-52.
162. Frances R, Chiva M, Sanchez E, et al. Bacterial translocation is downregulated by anti-TNF-alpha monoclonal antibody administration in rats with cirrhosis and ascites. J Hepatol 2007;46:797-803. (Pubitemid 46529037)
163. Adawi D, Kasrawi FB, Molin G, et al. Effect of lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat. Hepatology 1997;25:642-7. (Pubitemid 27106447)
164. Wang XD, Soltesz V, Molin G, et al. The role of oral administration of oatmeal fermented by Lactobacillus reuteri R2LC on bacterial translocation after acute liver failure induced by subtotal liver resection in the rat. Scand J Gastroenterol 1995;30:180-5.
165. Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-9. (Pubitemid 38569067)
166. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantationea randomized, double-blind trial. Am J Transplant 2005;5:125-30. (Pubitemid 40095136)